Open AccessExtracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis
Author(s) -
Rupesh Raina,
Joseph Wang,
Aditya Sharma,
Ronith Chakraborty
Publication year - 2020
Publication title -
blood purification
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 57
eISSN - 1421-9735
pISSN - 0253-5068
DOI - 10.1159/000506277
Subject(s) - medicine , focal segmental glomerulosclerosis , extracorporeal , nephrotic syndrome , minimal change disease , kidney disease , immunoadsorption , intensive care medicine , apheresis , urology , proteinuria , kidney , immunology , platelet , antibody
Focal segmental glomerulosclerosis (FSGS) is one of the most frequent and severe glomerular kidney disease with frequent progression to end-stage renal disease and a high rate of recurrence in renal transplantations. Due to intolerance or resistance to the current immunomodulatory treatments, the management of FSGS is a therapeutic challenge. Over the last few years, development in extracorporeal therapies has shown potential beneficial outcomes in drug-resistant and recurrent FSGS patients. Thus, this study reviews the current literature on the use of extracorporeal therapies, such as plasma exchange therapy, immunoadsorption, and low-density lipoprotein apheresis, for the treatment of FSGS in the pediatric population.